Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury
Launched by CENTRE INTEGRE UNIVERSITAIRE DE SANTE ET SERVICES SOCIAUX DU NORD DE L'ILE DE MONTREAL · Aug 19, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether starting treatment with a medication called baclofen right after a spinal cord injury (SCI) can help reduce spasticity—uncontrolled muscle tightness—and improve recovery. Spasticity can be a common problem after a spinal cord injury, and the goal is to see if treating it early with baclofen can lead to better outcomes in movement and overall function. Participants will be divided into two groups: one group will receive baclofen as soon as they show signs of spasticity, while the other group will receive standard care, where baclofen is given only if the spasticity becomes severe.
To be eligible for this trial, participants need to be at least 18 years old and have experienced a blunt spinal cord injury, with certain conditions in place regarding the severity and type of injury. Individuals with certain medical conditions or those unlikely to attend follow-up visits may not qualify. If you join the study, you can expect to take oral baclofen, starting with a low dose that may be increased over time, and you'll be monitored for safety and improvement in your physical abilities for up to six months. This trial is not yet recruiting participants, but it aims to find better ways to manage spasticity and improve recovery in individuals with spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female aged 18 years or older
- • Blunt (non-penetrating) traumatic SCI
- • AIS grade A to D
- • NLI between C0 and L1
- • Patient willing and able to provide informed consent
- Exclusion Criteria:
- • Non-traumatic SCI (e.g. tumor, infection, transverse myelitis, etc.)
- • AIS grade E upon admission
- • Penetrating tSCI (from stab wound, gunshot injury, etc.)
- • Cauda equina syndrome or NLI below L1
- • Moderate or severe brain injury (mild traumatic brain injury not an exclusion criteria)
- • Contraindication to oral baclofen use (needs clearance from attending physician and pharmacological consultant)
- • Pre-existing neurological disorders (cerebrovascular disease, Parkinson's disease, multiple sclerosis, etc.)
- • Major cognitive deficits precluding informed consent and/or assessments
- • Unlikely to comply with scheduled visits (e.g. living in another country)
- • Renal insufficiency
About Centre Integre Universitaire De Sante Et Services Sociaux Du Nord De L'ile De Montreal
The Centre intégré universitaire de santé et de services sociaux du Nord-de-l'île-de-Montréal (CIUSSS NIM) is a leading healthcare institution dedicated to providing comprehensive health and social services to the northern region of Montreal. As a clinical trial sponsor, CIUSSS NIM is committed to advancing medical research and improving patient care through innovative studies that adhere to the highest ethical standards. The organization collaborates with multidisciplinary teams to facilitate cutting-edge research initiatives, ensuring access to state-of-the-art treatments and therapies while prioritizing patient safety and community wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Andréane Richard-Denis, M.D., MSC
Principal Investigator
CIUSSS du Nord-de-l'île-de-Montréal-Hôpital du Sacré-Cœur de Montréal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported